Key result
In a patient with unresectable cardiac angiosarcoma, treatment with first-line weekly paclitaxel and second-line vinorelbine plus bevacizumab resulted in a progression-free survival of 6 months and overall survival of 7 months.
Why the study?
Does sequential chemotherapy with paclitaxel, vinorelbine, and bevacizumab improve survival in a patient with unresectable cardiac angiosarcoma?
Population
1 patient with unresectable cardiac angiosarcoma originating in the right atrium, with metastasis to lungs…
Design
Case_report
Follow-up
7 months
Authors
Loading...
Should not yet change practice in cardiac angiosarcoma; hypothesis-generating for systemic regimens in prospective studies.
Case Report (n=1)
Does sequential chemotherapy with paclitaxel, vinorelbine, and bevacizumab improve survival in a patient with unresectable cardiac angiosarcoma?
In a patient with unresectable cardiac angiosarcoma, sequential chemotherapy with paclitaxel followed by vinorelbine and bevacizumab resulted in a progression-free survival of 6 months and overall survival of 7 months.
Wang et al. (2017) conducted a case report in Unresectable cardiac angiosarcoma (n=1). Paclitaxel followed by vinorelbine and bevacizumab was evaluated on Progression-free survival and overall survival. In a patient with unresectable cardiac angiosarcoma, treatment with first-line weekly paclitaxel and second-line vinorelbine plus bevacizumab resulted in a progression-free survival of 6 months and overall survival of 7 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: